[Drug eluting stents in 2005: have the initial expectations been met?]

Area of Science:

• Cardiovascular medicine
• Biomedical engineering
• Interventional cardiology

Context:

• Percutaneous coronary intervention (PCI) can lead to neointimal hyperplasia and restenosis.
• Drug-eluting stents (DES) represent a significant technological advancement in managing post-PCI complications.
• Understanding the evolving role of DES is crucial for optimizing patient outcomes.

Purpose:

• To review the current clinical applications of drug-eluting stents.
• To explore the future directions and potential of DES technology.
• To summarize the findings of principal clinical trials evaluating DES efficacy and safety.

Summary:

• Drug-eluting stents deliver medication locally to inhibit cell proliferation, thereby preventing neointimal hyperplasia and restenosis.
• This review synthesizes data from major clinical trials, assessing the effectiveness of DES in diverse patient populations and lesion types.
• Current evidence supports the use of DES as a preferred strategy over bare-metal stents in most PCI scenarios.

Impact:

• Drug-eluting stents have transformed interventional cardiology by significantly reducing restenosis rates.
• The ongoing evolution of DES technology promises further improvements in long-term clinical outcomes for coronary artery disease patients.
• This review provides valuable insights for clinicians, researchers, and policymakers regarding the optimal utilization of DES.